Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026

HBM Holdings Limited (HKG: 2142) announced a strategic cooperation framework agreement with China National Pharmaceutical...

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Fineline Cube Jul 28, 2026

Antengene Corporation Limited (HKG: 6996) announced preliminary financial results for the six months ended June...

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026

China Medical System Holdings Limited (CMS) (HKG: 0867) announced that its Southeast Asia subsidiary, Rxilient...

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Fineline Cube Jul 28, 2026

Broncus Medical Inc. (HKG: 2216) announced that its self-developed BroncTru disposable bronchoscopic dilation catheter has...

Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class...

Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its innovative antibody-drug conjugate...

Company Drug

CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its...

Company Drug

Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials

Fineline Cube Jul 28, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical...

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026

InnoCare Pharma (HKG: 9969) announced that the pivotal Phase III clinical trial of its potent,...

Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Fineline Cube Jul 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that HRS-1780 tablets have received...

Company Drug

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Fineline Cube Jul 28, 2026

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that BIOS0635-048 tablets have received approval from...

Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Fineline Cube Jul 28, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced results from the Phase IIIb VOGUE study conducted by...

Company Drug

Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials

Fineline Cube Jul 28, 2026

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that SKB565, a dual-payload antibody-drug conjugate (ADC),...

Company

AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds

Fineline Cube Jul 28, 2026

AstraZeneca plc (NYSE: AZN) announced financial results for the second quarter and first half of...

Company Drug

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

Fineline Cube Jul 28, 2026

Alexion, AstraZeneca plc’s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III...

Company Drug

Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data

Fineline Cube Jul 27, 2026

Sanofi S.A. (NASDAQ: SNY) announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal...

Company Drug

Roche’s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System

Fineline Cube Jul 27, 2026

Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for...

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026

Home Control International Limited (HKG: 1747) announced it has entered into a strategic memorandum of...

Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026

Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (“Tempo Scan”) announced the...

Company Drug

Sichuan Biokin’s HER2 ADC T-Bren Enters Phase III Trial for Biliary Tract Cancer After Platinum Failure

Fineline Cube Jul 27, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its self-developed innovative biologic drug, T-Bren...

Posts pagination

1 2 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.